Chronic Refractory Cough Pipeline Landscape Report 2024 Featuring GSK and Trevi Therapeutics [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
Understanding Chronic Refractory Cough CRC presents a unique challenge within the medical community. Characterized by a persistent cough lasting more than eight weeks, the condition remains recalcitrant to conventional therapy even after comprehensive evaluation and treatment attempts. Patients with CRC face substantial detriments to their quality of life, grappling with physical discomfort, sleep disturbances, and social stigma. The complexity of managing this condition underscores the need for innovative therapeutic strategies. Advancements in Therapeutic Interventions Companies spearheading CRC drug development are testing therapies that represent a departure from traditional treatments. For instance, camlipixant (GSK5464714), a promising candidate in Phase III trials, is a P2X3 receptor antagonist that has demonstrated a significant reduction in cough frequency with a lower incidence of dysgeusia compared to other drugs in its class. GSK, a leading entity in this space, is
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024PR Newswire
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.MarketBeat
- Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024PR Newswire
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
TRVI
Earnings
- 8/8/24 - Miss
TRVI
Sec Filings
- 9/9/24 - Form 4
- 9/5/24 - Form 4
- 9/3/24 - Form 144
- TRVI's page on the SEC website